The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

Barbara J. Caldarone, Neil E. Paterson, Jia Zhou, Daniela Brunner, Alan P. Kozikowski, Koen G.C. Westphal, Gerdien A.H. Korte-Bouws, Jolanda Prins, S. Mechiel Korte, Berend Olivier, Afshin Ghavami

Research output: Contribution to journalArticlepeer-review

22 Scopus citations

Fingerprint

Dive into the research topics of 'The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties'. Together they form a unique fingerprint.

Medicine & Life Sciences